Provention Bio (NASDAQ:PRVB – Get Rating) had its price objective lowered by Chardan Capital from $30.00 to $25.00 in a report published on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.
Several other analysts have also recently weighed in on PRVB. HC Wainwright reduced their target price on shares of Provention Bio from $18.00 to $16.00 and set a buy rating on the stock in a report on Wednesday, February 15th. Jefferies Financial Group raised their target price on shares of Provention Bio from $18.00 to $22.00 and gave the company a buy rating in a report on Friday, November 18th. SVB Leerink raised their target price on shares of Provention Bio from $16.00 to $19.00 and gave the company an outperform rating in a report on Monday, November 21st. Oppenheimer raised their target price on shares of Provention Bio from $14.00 to $18.00 and gave the company an outperform rating in a report on Friday, November 18th. Finally, Cantor Fitzgerald cut shares of Provention Bio from an overweight rating to a neutral rating in a report on Monday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $20.00.
Provention Bio Stock Up 259.7 %
Shares of PRVB opened at $24.10 on Monday. The stock has a market capitalization of $2.10 billion, a PE ratio of -15.45 and a beta of 2.18. Provention Bio has a 1 year low of $3.18 and a 1 year high of $24.23. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.58 and a current ratio of 7.58. The company’s 50-day simple moving average is $9.25 and its 200-day simple moving average is $7.90.
Insider Buying and Selling at Provention Bio
Hedge Funds Weigh In On Provention Bio
A number of hedge funds have recently modified their holdings of PRVB. PNC Financial Services Group Inc. grew its position in shares of Provention Bio by 320.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,625 shares of the company’s stock worth $28,000 after acquiring an additional 2,000 shares during the last quarter. Dorsey Wright & Associates purchased a new position in shares of Provention Bio during the fourth quarter worth approximately $31,000. Royal Bank of Canada grew its position in shares of Provention Bio by 166.5% during the third quarter. Royal Bank of Canada now owns 7,769 shares of the company’s stock worth $35,000 after acquiring an additional 4,854 shares during the last quarter. OLD Mission Capital LLC purchased a new position in shares of Provention Bio during the second quarter worth approximately $41,000. Finally, Cantor Fitzgerald L. P. purchased a new position in shares of Provention Bio during the third quarter worth approximately $45,000. 37.39% of the stock is currently owned by hedge funds and other institutional investors.
Provention Bio Company Profile
Provention Bio, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset.
- Get a free copy of the StockNews.com research report on Provention Bio (PRVB)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.